arGEN-X to Present Results of Phase 1 Study of ARGX-110, a Novel Anti-CD70 Antibody, in Patients With Advanced Cancer at ASCO - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
arGEN-X to Present Results of Phase 1 Study of ARGX-110, a Novel Anti-CD70 Antibody, in Patients With Advanced Cancer at ASCO


arGEN-X to Present Results of Phase 1 Study of ARGX-110, a Novel Anti-CD70 Antibody, in Patients With Advanced Cancer at ASCO

PR Newswire

BREDA, The Netherlands and GHENT, Belgium, May 29, 2014 /PRNewswire/ --

arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA).

arGEN-X reported in December 2013 that this study met its translational development goals: all pre-specified biological activity measures (e.g. target saturation, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favorable safety profile and identified a dose that was advanced into a larger safety study in patients with a range of hematological and solid tumors. Patient recruitment into this expanded study began in January 2014 in Europe (ClinicalTrials.gov Identifier: NCT01813539) and top-line results are expected in 2015.

The results will be presented in a poster as follows:

Poster Session: Developmental Therapeutics - Immunotherapy

Abstract number:  #3023

Poster title: A Phase 1, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematological malignancies.

Date/time:  Monday 2 June, 1:15pm-4:15pm, Room S405

        Monday 2 June, 4:45pm-6:00pm, Room S406

Presenter: Ahmad Awada, Principal Investigator, Institut Jules Bordet

Authors: A. Awada[ 1 ], C. Rolfo[ 2 ], S. Rottey[ 3 ], L. Ysebrant de Lendonck[ 1 ], W. Schroyens[ 2 ], F. Offner[ 3 ], K. Silence[ 4 ], T. Dreier[ 4 ], M. Moshir[ 4 ], H. de Haard [ 4 ], M. Peeters[ 2 ], D. Bron[ 1 ], A. Thibault[ 4 ], P. Aftimos[ 1 ].

[ 1 ] Institut Jules Bordet, Université Libre de Bruxelles, Belgium;  [ 2 ] Universitair Ziekenhuis Antwerpen, Belgium;  [ 3 ] Universitair Ziekenhuis Gent, Belgium;  [ 4 ] arGEN-X BVBA, Belgium.

About ARGX-110 

ARGX-110 is a first-in-class monoclonal antibody that potently blocks CD70-induced tumor proliferation and tumor escape from immune surveillance. In addition, the POTELLIGENT®-enhanced antibody-dependent cellular cytotoxicity (ADCC) of ARGX-110 enables selective destruction of CD70-positive tumor cells. CD70 is overexpressed in the majority of cancer patients tested to date. Expectations of a favourable therapeutic index stem from its virtual absence in healthy tissues.

About the ARGX-110 Study 

The Phase 1 study (ClinicalTrials.gov Identifier: NCT01813539) consists of a dose-escalation phase followed by an adaptive safety study conducted in patients with advanced, refractory cancer. The patient enrichment strategy relies on individual tumor screening for CD70 utilizing a reproducible immunohistochemistry method. In addition to traditional clinical and PK/PD endpoints, biomarkers documenting the three modes of action of ARGX-110 are being evaluated. Patient enrolment is planned at approximately 90 CD70-positive patients with either hematological or solid tumors. The study is managed jointly by arGEN-X and a consortium of leading academic institutions in Belgium and France.

About arGEN-X  

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies - NHance®, ABDEG™ and POTELLIGENT® - further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell-killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

http://www.arGEN-X.com

For further information, please contact:  

Tim Van Hauwermeiren
Chief Executive Officer
T +32(0)9-243-40-70

Alain Thibault
Chief Medical Officer
E info@arGEN-X.com

Mark Swallow/David Dible
Citigate Dewe Rogerson
T +44-207-282-2949
arGEN-X@citigatedr.co.uk

Beth DelGiacco
Stern Investor Relations
+1-212-362-1200
beth@sternir.com


SOURCE arGEN-X

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here